STONEGATE CAPITAL PARTNERS UPDATES ITS COVERAGE OF AB SCIENCE’S STOCK WITH A DISCOUNTED CASH FLOW VALUATION MID-POINT OF EUR 4.25 PER SHARE AB Science SA (Euronext - FR0010557264 - AB) announces that ...
AB SCIENCE PRESENTS ITS ANNUAL FINANCIAL RESULTS AS OF 31 DECEMBER 2025 AND KEY EVENTS FOR THE PERIOD Paris, 13 May 2025, 7pm CET AB Science SA (Euronext - FR0010557264 - AB) today announces its ...
AB Science SA (Euronext - FR0010557264 - AB) announces that its stock continues to be covered by Maxim Group, an independent US-based full-service investment bank, securities and wealth management ...
The average one-year price target for AB Science (ENXTPA:AB) has been revised to €4.31 / share. This is an increase of 22.25% from the prior estimate of €3.53 dated September 27, 2025. The price ...
While AB Science believes these forward-looking statements are reasonable, investors are cautioned that these forward-looking statements are subject to numerous risks and uncertainties that are ...
AB Science has received a binding offer for a Clinical Trial Funding Insurance policy from Medical & Commercial International Ltd. (MCI), Lloyd’s Syndicate 1902, for its Phase III clinical trial ...
AB Science SA (Euronext - FR0010557264 - AB) today announced that it has filed an application for conditional Marketing Authorization to the European Medicines Agency (EMA) for Alsitek (masitinib) in ...
AB Science (ABSCF) is running a late-stage study of masitinib in progressive multiple sclerosis, a severe form of the disease with limited options. The trial, officially titled “A 96-Week, Prospective ...
AB Science SA (Euronext - FR0010557264 - AB) today announces the postponement of its annual general shareholders’ meeting. In the exceptional context of the Covid-19 pandemic and in accordance with ...
AB Science S.A. Annual stock financials by MarketWatch. View the latest AB financial statements, income statements and financial ratios.
i) Approval by several European countries to initiate the confirmatory Phase 3 trial AB Science announced in July 2025 that the confirmatory Phase 3 trial with masitinib in amyotrophic lateral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results